An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

641

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

May 19, 2025

Study Completion Date

May 19, 2025

Conditions
Asthma
Interventions
BIOLOGICAL

GSK3511294 (Depemokimab)

GSK3511294 (Depemokimab) will be administered using a pre-filled safety syringe.

Trial Locations (151)

168

GSK Investigational Site, Roma

807

GSK Investigational Site, Kaohsiung City

2100

GSK Investigational Site, Gödöllő

2450

GSK Investigational Site, Coffs Harbour

4101

GSK Investigational Site, South Brisbane

7900

GSK Investigational Site, Szigetvár

9200

GSK Investigational Site, Mosonmagyaróvár

10017

GSK Investigational Site, Hohhot

10367

GSK Investigational Site, Berlin

10461

GSK Investigational Site, The Bronx

13015

GSK Investigational Site, Marseille

14033

GSK Investigational Site, Caen

15706

GSK Investigational Site, Santiago de Compostela

15801

GSK Investigational Site, DuBois

17005

GSK Investigational Site, Girona

17033

GSK Investigational Site, Hershey

18014

GSK Investigational Site, Granada

20089

GSK Investigational Site, Rozzano MI

20122

GSK Investigational Site, Milan

22299

GSK Investigational Site, Hamburg

23561

GSK Investigational Site, Taipei

25123

GSK Investigational Site, Brescia

27100

GSK Investigational Site, Pavia

27103

GSK Investigational Site, Winston-Salem

28031

GSK Investigational Site, Madrid

28054

GSK Investigational Site, Gastonia

28078

GSK Investigational Site, Huntersville

28223

GSK Investigational Site, Pozuelo de AlarcOn Madr

29631

GSK Investigational Site, Benalmádena

31406

GSK Investigational Site, Savannah

32806

GSK Investigational Site, Orlando

33013

GSK Investigational Site, Hialeah

33014

GSK Investigational Site, Miami Lakes

33125

GSK Investigational Site, Miami

33134

GSK Investigational Site, Coral Gables

33144

GSK Investigational Site, Miami

33173

GSK Investigational Site, Miami

33186

GSK Investigational Site, Miami

33470

GSK Investigational Site, Loxahatchee Groves

36608

GSK Investigational Site, Gulfport

38601

GSK Investigational Site, Strakonice

39008

GSK Investigational Site, Santander

39120

GSK Investigational Site, Magdeburg

40201

GSK Investigational Site, Taichung

40509

GSK Investigational Site, Lexington

40705

GSK Investigational Site, Taichung

45229

GSK Investigational Site, Cincinnati

45231

GSK Investigational Site, Cincinnati

46010

GSK Investigational Site, Valencia

46015

GSK Investigational Site, Valencia

48013

GSK Investigational Site, Bilbao

48197

GSK Investigational Site, Ypsilanti

49300

GSK Investigational Site, Cholet

50009

GSK Investigational Site, Zaragoza

53100

GSK Investigational Site, Siena

55128

GSK Investigational Site, Mainz

56068

GSK Investigational Site, Koblenz

60389

GSK Investigational Site, Frankfurt

61761

GSK Investigational Site, Normal

63263

GSK Investigational Site, Neu-Isenburg

67091

GSK Investigational Site, Strasbourg

71122

GSK Investigational Site, Foggia

74011

GSK Investigational Site, Annecy

75013

GSK Investigational Site, Allen

75225

GSK Investigational Site, Dallas

78006

GSK Investigational Site, Boerne

78028

GSK Investigational Site, Kerrville

78207

GSK Investigational Site, San Antonio

78229

GSK Investigational Site, San Antonio

80026

GSK Investigational Site, Lafayette

80923

GSK Investigational Site, Colorado Springs

90127

GSK Investigational Site, Palermo

93534

GSK Investigational Site, Lancaster

98158

GSK Investigational Site, Messina

98225

GSK Investigational Site, Bellingham

110004

GSK Investigational Site, Shenyang

110016

GSK Investigational Site, Shenyang

130021

GSK Investigational Site, Changchun

132011

GSK Investigational Site, Changchun

200040

GSK Investigational Site, Shanghai

200090

GSK Investigational Site, Shanghai

221006

GSK Investigational Site, Xuzhou

230001

GSK Investigational Site, Hefei

250014

GSK Investigational Site, Jinan

310009

GSK Investigational Site, Hangzhou

323027

GSK Investigational Site, Wenzhou

410013

GSK Investigational Site, Changsha

430030

GSK Investigational Site, Wuhan

510080

GSK Investigational Site, Guangzhou

510120

GSK Investigational Site, Guangzhou

510150

GSK Investigational Site, Guangzhou

510180

GSK Investigational Site, Guangzhou

570311

GSK Investigational Site, Haikou

610041

GSK Investigational Site, Chengdu

830054

GSK Investigational Site, Ürümqi

08225

GSK Investigational Site, Northfield

T8H 0N2

GSK Investigational Site, Sherwood Park

V2C 5T1

GSK Investigational Site, Kamloops

L1S 2J5

GSK Investigational Site, Ajax

K1G 6C6

GSK Investigational Site, Ottawa

N8X 1T3

GSK Investigational Site, Windsor

625 00

GSK Investigational Site, Brno

500 05

GSK Investigational Site, Hradec Králové

377 01

GSK Investigational Site, Jindřichův Hradec

779 00

GSK Investigational Site, Olomouc

390 02

GSK Investigational Site, Tábor

415 01

GSK Investigational Site, Teplice

04275

GSK Investigational Site, Leipzig

04357

GSK Investigational Site, Leipzig

09042

GSK Investigational Site, Monserrato CA

470-1192

GSK Investigational Site, Aichi

489-8642

GSK Investigational Site, Aichi

275-8580

GSK Investigational Site, Chiba

802-0052

GSK Investigational Site, Fukuoka

811-1394

GSK Investigational Site, Fukuoka

813-0017

GSK Investigational Site, Fukuoka

960-1295

GSK Investigational Site, Fukushima

734-8530

GSK Investigational Site, Hiroshima

053-8506

GSK Investigational Site, Hokkaido

064-0804

GSK Investigational Site, Hokkaido

761-8073

GSK Investigational Site, Kagawa

762-8550

GSK Investigational Site, Kagawa

890-8520

GSK Investigational Site, Kagoshima

231-8682

GSK Investigational Site, Kanagawa

232-0024

GSK Investigational Site, Kanagawa

951-8520

GSK Investigational Site, Niigata

702-8055

GSK Investigational Site, Okayama

843-0393

GSK Investigational Site, Saga

103-0027

GSK Investigational Site, Tokyo

141-8625

GSK Investigational Site, Tokyo

158-0097

GSK Investigational Site, Tokyo

185-0014

GSK Investigational Site, Tokyo

204-8585

GSK Investigational Site, Tokyo

80-214

GSK Investigational Site, Gdansk

25-355

GSK Investigational Site, Kielce

30-033

GSK Investigational Site, Krakow

31-624

GSK Investigational Site, Krakow

90-242

GSK Investigational Site, Lodz

20-552

GSK Investigational Site, Lublin

27-400

GSK Investigational Site, Ostrowiec Świętokrzyski

35-051

GSK Investigational Site, Rzeszów

47-120

GSK Investigational Site, Strzelce Opolskie

54-239

GSK Investigational Site, Wroclaw

08006

GSK Investigational Site, Barcelona

CP 28041

GSK Investigational Site, Madrid

07010

GSK Investigational Site, Palma de Mallorca

BD9 6RJ

GSK Investigational Site, Bradford

KT16 0PZ

GSK Investigational Site, Chertsey

EC1M 6BQ

GSK Investigational Site, London

M8 5RB

GSK Investigational Site, Manchester

NG5 1PB

GSK Investigational Site, Nottingham

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Iqvia Pty Ltd

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY

NCT05243680 - An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) | Biotech Hunter | Biotech Hunter